West Pharmaceutical Services (WST) reported a strong fourth quarter and full-year 2025, with earnings and sales surpassing analyst expectations. The company also announced plans to sell its SmartDose 3.5ml product to AbbVie by mid-2026 and provided optimistic guidance for 2026, driven by robust performance in its Proprietary Products segment and HVP growth. The stock rose following the announcement, reflecting investor confidence in its strategic execution and future outlook.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up
West Pharmaceutical Services (WST) reported a strong fourth quarter and full-year 2025, with earnings and sales surpassing analyst expectations. The company also announced plans to sell its SmartDose 3.5ml product to AbbVie by mid-2026 and provided optimistic guidance for 2026, driven by robust performance in its Proprietary Products segment and HVP growth. The stock rose following the announcement, reflecting investor confidence in its strategic execution and future outlook.